Latest Roche Stories
PRINCETON, N.J., April 25, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended March 31, 2011. Financial Results Revenues were $0.2 million during the quarter ended March 31, 2011 compared to $0.3 million for the quarter ended March 31, 2010 and include amortization of...
ATLANTIC CITY, N.J., April 8, 2011 /PRNewswire/ -- Hagens Berman LLP, a nationally recognized law firm today praised a jury's verdict that ordered pharmaceutical company Roche (ROG:VX) to pay $2 million to a woman who suffered serious gastrointestinal damage caused by the drug Accutane, while denying similar claims of actor James Marshall and another plaintiff. (Logo: http://photos.prnewswire.com/prnh/20080317/AQM144LOGO) Accutane, along with its active ingredient, isotretinoin, was...
NUTLEY, N.J., March 28, 2011 /PRNewswire/ -- Roche announced today that Janet Hammond, MD, Ph.D., has joined the company as Vice President, Translational Medicine - Virology in Pharmaceutical Research and Early Development (pRED). In her new role, Janet will report to Jacques Banchereau, Ph.D., Discovery and Translational Area (DTA) Head for Inflammation and Virology, and Chief Scientific Officer at Nutley, and be responsible for driving strategy and implementation of early clinical...
MADISON, Wis., March 22, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI) announced today that their two-year collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) to substantiate CDI's iCell® Cardiomyocytes as a predictive tool for assessing the potential cardiotoxic effects of developing drug candidates was completed early and is now transitioning into a standard supply agreement. Moving forward, iCell Cardiomyocytes, induced pluripotent stem cell (iPSC)-derived human heart...
INDIANAPOLIS and FORT BRAGG, N.C., Feb. 23, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received approval from the U.S. Department of Defense (DOD) to provide remote service and support for its lab analyzers at Womack Army Medical Center through the DOD's secure B2B gateway. Roche is the first in-vitro (test tube) diagnostics manufacturer to be approved by the DOD for this remote access. The B2B gateway is a highly secure portal that enables external...
SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the first patient received subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze((TM) technology (rHuPH20, recombinant human hyaluronidase). This represents the second Roche cancer medicine, in addition to Herceptin® SC (trastuzumab), to enter a Phase 3 registration study as part of the...
PRINCETON, N.J., Feb. 7, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended December 31, 2010. Financial Results Revenues were $0.2 million during the quarter ended December 31, 2010 compared to $0.3 million for the quarter ended December 31, 2009 and include amortization...
MANNHEIM, Germany, Feb. 1, 2011 /PRNewswire/ -- An innovative diabetes management concept including structured self-monitoring of blood glucose (SMBG), data visualization, pattern analysis and derived therapy adjustments can significantly reduce HbA1c values, improve glycemic control and enhance patients' quality of life. These are the key findings of the 12-month data from the Structured Testing Protocol (STeP) Study, newly published in Diabetes Care.(1) Self-monitoring of blood glucose...
Focus on cancer vaccines, auto-immune disease diagnostics and treatment DALLAS, Dec. 3, 2010 /PRNewswire-USNewswire/ -- Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI. These programs will leverage BIIR's...
PRINCETON, N.J., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2010. At fiscal year end Pharmasset held $127.1 million in cash and cash equivalents. Pipeline Update and 2010 highlights RG7128 Phase 2b PROPEL and JUMP-C trials...
